Millennium Management LLC Has $14.80 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN)

Millennium Management LLC lowered its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 14.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,714,402 shares of the company's stock after selling 772,770 shares during the quarter. Millennium Management LLC owned 4.70% of Acelyrin worth $14,803,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in Acelyrin by 21.9% in the fourth quarter. Wells Fargo & Company MN now owns 52,014 shares of the company's stock valued at $163,000 after purchasing an additional 9,332 shares in the last quarter. XTX Topco Ltd purchased a new stake in Acelyrin in the 4th quarter valued at $33,000. Boothbay Fund Management LLC grew its stake in Acelyrin by 54.8% in the 4th quarter. Boothbay Fund Management LLC now owns 29,828 shares of the company's stock valued at $94,000 after purchasing an additional 10,554 shares during the period. Intech Investment Management LLC grew its stake in shares of Acelyrin by 71.0% during the 4th quarter. Intech Investment Management LLC now owns 26,587 shares of the company's stock worth $83,000 after acquiring an additional 11,040 shares during the period. Finally, 4WEALTH Advisors Inc. purchased a new stake in Acelyrin during the 4th quarter worth about $35,000. Institutional investors and hedge funds own 87.31% of the company's stock.

Acelyrin Stock Performance

Shares of NASDAQ SLRN remained flat at $2.27 during trading hours on Wednesday. The company has a 50 day moving average price of $2.34 and a 200-day moving average price of $2.80. Acelyrin, Inc. has a 52-week low of $1.85 and a 52-week high of $7.25. The firm has a market cap of $229.17 million, a P/E ratio of -0.92 and a beta of 1.07.

Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.40. On average, sell-side analysts anticipate that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Mina Kim sold 17,986 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the sale, the chief executive officer now directly owns 671,753 shares of the company's stock, valued at approximately $1,840,603.22. This represents a 2.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.60% of the stock is currently owned by corporate insiders.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.